Exhibit O

Ascension and AMSURG - Redaction Log to HCMO Notice of Material Change Form

BATES NUMBER	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
Ascension_HCMO _02426 - Ascension_HCMO _02444	Ascension and AMSURG	HCMO-1 Confidential Appendix	FEINs; personal contact information; negotiation and transaction process; future federal and state filings; Ascension's business operations in Oregon; transaction history; anticipated changes resulting from the proposed transaction	The Parties request confidential treatment of the Supplemental Answers to HCMO-1. The redacted information relating to personal contact information; the negotiation and transaction process; federal and state filings; Ascension's business operations in Oregon; the parties' transaction history; and anticipated changes resulting from the proposed transaction are confidential and have not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to the Parties. (See ORS ORS 192.377; ORS 192.345(2)).  Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing "all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction." As such, the Parties are requesting further confidential treatment of these materials.  As agreed, FEINs will be redacted for the public form posting, but may be made available
Ascension_HCMO _00004 - Ascension_HCMO _00009	Ascension and AMSURG	HCMO-1b	FEINs	upon request.  As agreed, FEINs will be redacted for the public form posting, but may be made available upon request.

Exhibit O

Ascension and AMSURG - Redaction Log to HCMO Notice of Material Change Form

AMSURG			The Parties request confidential treatment of the redacted information submitted in response to HCMO-1c. The redacted service area zip codes are confidential, nonpublic, and competitively sensitive. Disclosure of the redacted information would cause commercial harm to the Parties. (See ORS 192.345(2)).
			Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing "all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction." As such, the Parties are requesting further confidential treatment of these materials.
Ascension	HSR Filing and filing attachments, including E4-E5 Diligence Reports and E24 Purchase Agreement	Entire Document	Ascension requests confidential treatment of the HSR Filing and Filing Attachments. These documents are confidential and have not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to Ascension. (See ORS 192.345(2)).  Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing "all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction." As such, Ascension is requesting further
_	Ascension	including E4-E5 Diligence Reports	including E4-E5 Diligence Reports

Exhibit O

Ascension and AMSURG - Redaction Log to HCMO Notice of Material Change Form

AMSURG_HCMO _000001 - AMSURG_HCMO _003575	AMSURG	HSR Filing and filing attachments	Entire Document	AMSURG requests confidential treatment of the HSR Filing and Filing Attachments. These documents are confidential and have not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to AMSURG. (See ORS 192.345(2)).  Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing "all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction." As such, AMSURG is requesting further confidential treatment of these materials.
Ascension_HCMO _01658 - Ascension_HCMO _01669	Ascension	Bylaws	Entire Document	Ascension requests confidential treatment of the nonpublic Bylaws. These documents have not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to Ascension. (See ORS 192.345(2)).  Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing "all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction." As such, Ascension is requesting further
Ascension_HCMO _01670 - Ascension_HCMO _02246	AMSURG	Governance Documents	Entire Document	confidential treatment of these materials.  AMSURG requests confidential treatment of the nonpublic governance documents. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to

Exhibit O

Ascension and AMSURG - Redaction Log to HCMO Notice of Material Change Form

		Trivisored Reduction Log to		AMSURG. (See ORS 192.345(2)).
				Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing "all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction." As such, AMSURG is requesting further confidential treatment of these materials.
Ascension_HCMO _02247 - Ascension_HCMO _02257	Ascension	Project Bluegrass Holdco Governance Documents	Entire Document	Ascension requests confidential treatment of the nonpublic governance documents for Project Bluegrass Holdco. These documents have not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to Ascension. (See ORS 192.345(2)).  Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing "all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction." As such, Ascension is requesting further confidential treatment of these materials.
Ascension_HCMO _02395 - Ascension_HCMO _02425; Ascension_HCMO _02445 - Ascension_HCMO _02545	AMSURG	Financial Statements	Entire Document	AMSURG requests confidential treatment of the financial statements. As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to AMSURG. (See ORS 192.345(2)).  Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing "all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction." As such, AMSURG is requesting further

Exhibit O

Ascension and AMSURG - Redaction Log to HCMO Notice of Material Change Form

				confidential treatment of these materials.
Ascension_HCMO	Ascension	Diligence Report (Deloitte)	Entire Document	Ascension requests confidential treatment of its
_01574 -				due diligence report. This document contains
Ascension_HCMO				information about strategic plans that is
_01631				competitively sensitive and this information has
				not been made publicly available in any other
				forum. Disclosure of this competitively
				sensitive information would cause commercial
				harm to Ascension. (See ORS 192.345(2)).
				H. 1. ODG 415 501/12\/\) TIL O
				Under ORS 415.501(13)(c), The Oregon Health
				Authority is prohibited from disclosing "all
				confidential information and documents that are
				not publicly available that are obtained in
				relation to a material change transaction." As
				such, Ascension is requesting further
				confidential treatment of these materials.